Hookipa appoints Michael Kelly as independent director

Company
Hookipa Pharma Inc
Appointee name
Michael Kelly
Country

Austria

Hookipa Pharma Inc has appointed former Amgen Inc executive Michael Kelly as an independent director to guide it through the development of its immunotherapy portfolio for infectious diseases and cancers. Mr Kelly is currently president of Sentry Hill Partners LLC consultancy. Prior to his management positions at Amgen, he held executive positions at Tanox Inc, Biogen Idec and Monsanto Life Sciences.

Mr Kelly holds a BSc in business administration from Florida A&M University, concentrating in finance and industrial relations.

Hookipa announced the appointment on 15 February 2019.

Copyright 2019 Evernow Publishing Ltd